Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AnaptysBio, Momenta Enter Antibody Development Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

AnaptysBio, Momenta Enter Antibody Development Pact

To employ AnaptysBio's platform technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AnaptysBio, Inc. has initiated an antibody development program with Momenta Pharmaceuticals focused on the development of novel antibodies against an undisclosed target. AnaptysBio will receive an upfront fee in exchange for an option to acquire antibodies generated using its SHM-XEL platform against a specific therapeutic target. Financial terms were not disclosed.
 
“AnaptysBio’s platform technology and antibody development capabilities have been strongly validated by numerous successful partnerships,” said Hamza Suria, AnaptysBio’s president and chief executive officer. “We look forward to working with Momenta on the development of these exciting new antibodies for unmet medical needs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics